Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Phase 2, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Filgotinib, GS-9876 and GS-4059 in Adult Subjects With Active Sjogren's Syndrome

Trial Profile

A Randomized, Phase 2, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Filgotinib, GS-9876 and GS-4059 in Adult Subjects With Active Sjogren's Syndrome

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Nov 2018

At a glance

  • Drugs Filgotinib (Primary) ; GS 9876 (Primary) ; Tirabrutinib (Primary)
  • Indications Sjogren's syndrome
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 25 Oct 2018 Status changed from recruiting to active, no longer recruiting.
    • 25 Apr 2018 Planned End Date changed from 1 May 2019 to 1 Dec 2019.
    • 25 Apr 2018 Planned primary completion date changed from 1 Aug 2018 to 1 Mar 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top